Steady Earnings and Returns
Q4 net investment income (NII) of $0.40 per share (flat QoQ) and net income of $0.46 per share; Q4 net income annualized return on average equity of 10.1%. Full-year 2025 net income of $1.70 per share representing a 9.3% return on average equity.
Portfolio Growth and Scale
Comprehensive portfolio of $3.3 billion at year-end with annual growth of 7.2% and average exposure per borrower of $3.8 million.
Strong Origination Momentum
Q4 originations of $462 million (second-highest on record), up 36% year-over-year and 3% quarter-over-quarter; full-year originations of $1.84 billion.
Shift to Asset-Based Specialty Finance
More than 83% of portfolio in senior secured specialty finance loans (highest percentage in 20-year history); ABL originations of $247 million in Q4 (almost double prior-year period) and $1.1 billion for the year (nearly double 2024).
High Credit Quality and Low Problem Loans
Approximately 95% of comprehensive portfolio in first lien senior secured loans; 100% of investments at cost performing with zero non-accruals; PIK income de minimis (~1–2% of total income depending on metric cited).
Attractive Yields Across Key Verticals
Weighted average portfolio yield of 11.6% (Q4); ABL asset-level weighted average yield 12.6%; life science first-lien weighted average yield 12.3%; equipment finance weighted average yield ~11%.
Strong Liquidity and Funding Profile
Over $850 million of available capital to deploy (including credit facility capacity and specialty finance capacity); approximately $1.2 billion of debt outstanding with net debt-to-equity of 1.14x (within target range); next unsecured note maturity in December 2026; investment-grade ratings from Fitch, Moody's and DBRS.
Successful Liability Management
Refinanced SSLP revolving facility reducing spread by 75 basis points (from SOFR+2.90% to SOFR+2.15%); improved borrowing flexibility, advance rates and extended maturities.
Shareholder-Friendly Actions and Alignment
Board declared Q1 2026 quarterly base distribution of $0.41 per share; management and SLR team own over 8% of the company and significant incentive compensation is invested in SLR stock; dividend yield ~11.2% at recent market close.
Diversification and Defensive Positioning
Very low direct exposure to software (~2% of portfolio) and concentrated emphasis on asset-backed strategies (ABL, equipment finance, life sciences) designed for downside protection and active collateral monitoring.